<p>Assenagon Asset Management S.A. 在最近向美国证券交易委员会提交的文件中表示，在第三季度将其在 Sarepta Therapeutics, Inc.（NASDAQ:SRPT - 免费报告）的持股减少了 96.6%。该机构投资者在季度内出售了 838,457 股后，持有该生物技术公司 29,482 股股票。Assenagon Asset Management S.A. 在 Sarepta Therapeutics 的持股在最近一个季度末价值 568,000 美元。</p>
<p>获取 <strong>Sarepta Therapeutics</strong> 的提醒：</p>
<ul>
<li>Sarepta 在 2025 年遭遇重创——分析师仍然预测 179% 的上涨空间</li>
</ul>
<p>其他几家对冲基金和机构投资者最近也对该公司的持股进行了调整。Ancora Advisors LLC 在第一季度将其在 Sarepta Therapeutics 的持股增加了 150.0%。Ancora Advisors LLC 目前持有 500 股该生物技术公司的股票，价值 32,000 美元，此前在上个季度又增持了 300 股。Banque Transatlantique SA 在第一季度购买了 Sarepta Therapeutics 的新股份，价值 44,000 美元。AlphaQuest LLC 在第一季度购买了 Sarepta Therapeutics 的新股份，价值 141,000 美元。GAMMA Investing LLC 在第三季度将其在 Sarepta Therapeutics 的持股增加了 285.6%。GAMMA Investing LLC 目前持有 3,089 股该生物技术公司的股票，价值 60,000 美元，此前在上个季度又购买了 2,288 股。最后，Blue Trust Inc. 在第二季度将其在 Sarepta Therapeutics 的持股增加了 542.3%。Blue Trust Inc. 目前持有 3,282 股该生物技术公司的股票，价值 56,000 美元，此前在上个季度又购买了 2,771 股。机构投资者持有该公司 86.68% 的股票。</p>
<h2>分析师设定新目标价</h2>
<p>几位股票研究分析师最近对 SRPT 股票发表了评论。富国银行将 Sarepta Therapeutics 的目标价从 50.00 美元下调至 45.00 美元，并在 11 月 5 日的报告中对该公司给予了 “增持” 评级。Robert W. Baird 将 Sarepta Therapeutics 的目标价从 21.00 美元下调至 15.00 美元，并在 11 月 4 日的研究报告中对该公司给予了 “中性” 评级。Weiss Ratings 在一份研究报告中重申了对 Sarepta Therapeutics 的 “卖出（d）” 评级。美国银行在 10 月 22 日的研究报告中将 Sarepta Therapeutics 的目标价从 16.00 美元上调至 18.00 美元，并给予该股票 “表现不佳” 的评级。最后，Leerink Partners 在 9 月 9 日的研究报告中将 Sarepta Therapeutics 的目标价从 12.00 美元上调至 15.00 美元，并给予该公司 “市场表现” 的评级。九位分析师对该股票给予了买入评级，十五位分析师给予了持有评级，六位分析师给予了卖出评级。根据 MarketBeat 的数据，该股票目前的共识评级为 “持有”，共识目标价为 33.68 美元。</p>
<ul>
<li>Sarepta 因致死事件下跌 42%；市场关注 Solid Biosciences</li>
</ul>
<p><strong>获取我们最新的 Sarepta Therapeutics 股票分析</strong></p>
<h2>内部人士下注</h2>
<p>在其他 Sarepta Therapeutics 的新闻中，首席运营官 Ian Michael Estepan 于 12 月 16 日星期二出售了 13,187 股该股票。该股票的平均售价为 22.31 美元，总交易额为 294,201.97 美元。出售完成后，首席运营官直接持有该公司 193,300 股股票，价值 4,312,523 美元。这笔交易代表其持股减少了 6.39%。该交易已在向美国证券交易委员会的文件中披露，相关文件可通过美国证券交易委员会网站获取。7.60% 的股票由内部人士持有。</p>
<h2>Sarepta Therapeutics 股票上涨 1.3%</h2>
<ul>
<li>制药行业抛售：3 只 RSI 指标显示你不应忽视的股票</li>
</ul>
<p>Sarepta Therapeutics 股票在周五开盘价为 22.29 美元。Sarepta Therapeutics, Inc. 的 52 周低点为 10.41 美元，52 周高点为 129.84 美元。该公司的债务与股本比率为 0.78，速动比率为 1.79，流动比率为 2.95。该公司的市值为 23.4 亿美元，市盈率为 -7.41，贝塔值为 0.54。该公司的 50 日移动平均线为 20.74 美元，200 日移动平均线为 20.02 美元。</p>
<p>Sarepta Therapeutics（NASDAQ:SRPT - 获取免费报告）最近在 11 月 3 日星期一公布了季度财报。该生物技术公司报告季度每股收益为（0.13）美元，低于市场共识预期的 0.02 美元，差距为（0.15）美元。该公司在季度内的收入为 3.9936 亿美元，而分析师预期为 3.3151 亿美元。Sarepta Therapeutics 的净利润率为 -11.25%，股本回报率为 -4.85%。Sarepta Therapeutics 的收入同比下降了 14.5%。在去年同期，该公司每股收益为 0.62 美元。平均而言，卖方分析师预计 Sarepta Therapeutics, Inc. 在当前财政年度的每股收益将达到 2.67 美元。</p>
<h2>Sarepta Therapeutics 公司简介</h2>
<p>（免费报告）</p>
<p>Sarepta Therapeutics, Inc. 是一家生物制药公司，专注于针对罕见神经肌肉疾病的精准基因治疗的发现和开发。公司总部位于马萨诸塞州剑桥，Sarepta 的核心专长在于设计针对 RNA 的疗法和基因疗法，以解决潜在的基因突变。公司的使命是通过创新的治疗方式改变杜氏肌营养不良症（DMD）及相关疾病患者的治疗模式。</p>
<p>Sarepta 的商业产品包括几种已获得美国批准的外显子跳跃疗法。</p>
<h2>进一步阅读</h2>
<ul>
<li>五只我们更看好的股票，胜过 Sarepta Therapeutics</li>
<li>在 1 月 1 日之前投资 1,000 美元于此股票 [非 NVDA]</li>
<li>将你的 “死钱” 转变为每月 306 美元以上（从本月开始）</li>
<li>华盛顿为战争做准备</li>
<li>奇怪的水晶金属性能超越硅达 100 倍</li>
<li>33,000% 的奇怪新 “AI 燃料” 带来的繁荣？</li>
</ul>
<p><strong>想知道其他对 SRPT 持有的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取 Sarepta Therapeutics, Inc. (NASDAQ:SRPT - 免费报告) 的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1JQVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1JQVA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Sarepta Therapeutics 吗？</h2>
<p>在考虑 Sarepta Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Sarepta Therapeutics 并不在名单上。</p>
<p>虽然 Sarepta Therapeutics 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

Sarepta医疗

<p>Assenagon Asset Management S.A. 在第三季度大幅减少了对 Sarepta Therapeutics, Inc. 的持股，减持幅度达到 96.6%，出售了 838,457 股。剩余的 29,482 股价值 568,000 美元。其他几家机构投资者也调整了在该公司的持仓。分析师对 Sarepta 的评级意见不一，普遍评级为 “持有”，目标价为 33.68 美元。Sarepta 的股票开盘价为 22.29 美元，市值为 23.4 亿美元</p>

<p>Assenagon Asset Management S.A. reduced its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 96.6% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 29,482 shares of the biotechnology company's stock after selling 838,457 shares during the quarter. Assenagon Asset Management S.A.'s holdings in Sarepta Therapeutics were worth $568,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>Assenagon Asset Management S.A. 在最近向美国证券交易委员会提交的文件中表示，在第三季度将其在 Sarepta Therapeutics, Inc.（NASDAQ:SRPT - 免费报告）的持股减少了 96.6%。该机构投资者在季度内出售了 838,457 股后，持有该生物技术公司 29,482 股股票。Assenagon Asset Management S.A. 在 Sarepta Therapeutics 的持股在最近一个季度末价值 568,000 美元。</p>
</div><p>Get <strong>Sarepta Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Sarepta Therapeutics</strong> 的提醒：</p>
</div><ul>
<li>Brutal 2025 for Sarepta—Analysts Still Call for 179% Upside</li>
</ul>
<div class="lb-trans"><ul>
<li>Sarepta 在 2025 年遭遇重创——分析师仍然预测 179% 的上涨空间</li>
</ul>
</div><p>Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. Ancora Advisors LLC increased its position in shares of Sarepta Therapeutics by 150.0% during the first quarter. Ancora Advisors LLC now owns 500 shares of the biotechnology company's stock valued at $32,000 after acquiring an additional 300 shares in the last quarter. Banque Transatlantique SA purchased a new stake in Sarepta Therapeutics during the 1st quarter valued at $44,000. AlphaQuest LLC bought a new stake in shares of Sarepta Therapeutics in the 1st quarter worth $141,000. GAMMA Investing LLC increased its holdings in shares of Sarepta Therapeutics by 285.6% in the 3rd quarter. GAMMA Investing LLC now owns 3,089 shares of the biotechnology company's stock worth $60,000 after purchasing an additional 2,288 shares in the last quarter. Finally, Blue Trust Inc. raised its stake in shares of Sarepta Therapeutics by 542.3% in the second quarter. Blue Trust Inc. now owns 3,282 shares of the biotechnology company's stock worth $56,000 after purchasing an additional 2,771 shares during the last quarter. Institutional investors own 86.68% of the company's stock.</p>
<div class="lb-trans"><p>其他几家对冲基金和机构投资者最近也对该公司的持股进行了调整。Ancora Advisors LLC 在第一季度将其在 Sarepta Therapeutics 的持股增加了 150.0%。Ancora Advisors LLC 目前持有 500 股该生物技术公司的股票，价值 32,000 美元，此前在上个季度又增持了 300 股。Banque Transatlantique SA 在第一季度购买了 Sarepta Therapeutics 的新股份，价值 44,000 美元。AlphaQuest LLC 在第一季度购买了 Sarepta Therapeutics 的新股份，价值 141,000 美元。GAMMA Investing LLC 在第三季度将其在 Sarepta Therapeutics 的持股增加了 285.6%。GAMMA Investing LLC 目前持有 3,089 股该生物技术公司的股票，价值 60,000 美元，此前在上个季度又购买了 2,288 股。最后，Blue Trust Inc. 在第二季度将其在 Sarepta Therapeutics 的持股增加了 542.3%。Blue Trust Inc. 目前持有 3,282 股该生物技术公司的股票，价值 56,000 美元，此前在上个季度又购买了 2,771 股。机构投资者持有该公司 86.68% 的股票。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>Several equities research analysts recently commented on SRPT shares. Wells Fargo &amp; Company reduced their price objective on Sarepta Therapeutics from $50.00 to $45.00 and set an &#34;overweight&#34; rating for the company in a report on Wednesday, November 5th. Robert W. Baird reduced their price target on shares of Sarepta Therapeutics from $21.00 to $15.00 and set a &#34;neutral&#34; rating for the company in a research note on Tuesday, November 4th. Weiss Ratings restated a &#34;sell (d)&#34; rating on shares of Sarepta Therapeutics in a research report on Monday. Bank of America lifted their target price on shares of Sarepta Therapeutics from $16.00 to $18.00 and gave the stock an &#34;underperform&#34; rating in a research report on Wednesday, October 22nd. Finally, Leerink Partners boosted their target price on shares of Sarepta Therapeutics from $12.00 to $15.00 and gave the company a &#34;market perform&#34; rating in a research note on Tuesday, September 9th. Nine analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and six have assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of &#34;Hold&#34; and a consensus target price of $33.68.</p>
<div class="lb-trans"><p>几位股票研究分析师最近对 SRPT 股票发表了评论。富国银行将 Sarepta Therapeutics 的目标价从 50.00 美元下调至 45.00 美元，并在 11 月 5 日的报告中对该公司给予了 “增持” 评级。Robert W. Baird 将 Sarepta Therapeutics 的目标价从 21.00 美元下调至 15.00 美元，并在 11 月 4 日的研究报告中对该公司给予了 “中性” 评级。Weiss Ratings 在一份研究报告中重申了对 Sarepta Therapeutics 的 “卖出（d）” 评级。美国银行在 10 月 22 日的研究报告中将 Sarepta Therapeutics 的目标价从 16.00 美元上调至 18.00 美元，并给予该股票 “表现不佳” 的评级。最后，Leerink Partners 在 9 月 9 日的研究报告中将 Sarepta Therapeutics 的目标价从 12.00 美元上调至 15.00 美元，并给予该公司 “市场表现” 的评级。九位分析师对该股票给予了买入评级，十五位分析师给予了持有评级，六位分析师给予了卖出评级。根据 MarketBeat 的数据，该股票目前的共识评级为 “持有”，共识目标价为 33.68 美元。</p>
</div><ul>
<li>Sarepta Drops 42% on Fatalities; Markets Eye Solid Biosciences</li>
</ul>
<div class="lb-trans"><ul>
<li>Sarepta 因致死事件下跌 42%；市场关注 Solid Biosciences</li>
</ul>
</div><p><strong>Get Our Latest Stock Analysis on Sarepta Therapeutics</strong></p>
<div class="lb-trans"><p><strong>获取我们最新的 Sarepta Therapeutics 股票分析</strong></p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><p>In other Sarepta Therapeutics news, COO Ian Michael Estepan sold 13,187 shares of the stock in a transaction that occurred on Tuesday, December 16th. The shares were sold at an average price of $22.31, for a total transaction of $294,201.97. Following the completion of the sale, the chief operating officer directly owned 193,300 shares of the company's stock, valued at $4,312,523. This trade represents a 6.39% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 7.60% of the stock is owned by insiders.</p>
<div class="lb-trans"><p>在其他 Sarepta Therapeutics 的新闻中，首席运营官 Ian Michael Estepan 于 12 月 16 日星期二出售了 13,187 股该股票。该股票的平均售价为 22.31 美元，总交易额为 294,201.97 美元。出售完成后，首席运营官直接持有该公司 193,300 股股票，价值 4,312,523 美元。这笔交易代表其持股减少了 6.39%。该交易已在向美国证券交易委员会的文件中披露，相关文件可通过美国证券交易委员会网站获取。7.60% 的股票由内部人士持有。</p>
</div><h2>Sarepta Therapeutics Trading Up 1.3%</h2>
<div class="lb-trans"><h2>Sarepta Therapeutics 股票上涨 1.3%</h2>
</div><ul>
<li>Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t Ignore</li>
</ul>
<div class="lb-trans"><ul>
<li>制药行业抛售：3 只 RSI 指标显示你不应忽视的股票</li>
</ul>
</div><p>Shares of Sarepta Therapeutics stock opened at $22.29 on Friday. Sarepta Therapeutics, Inc. has a fifty-two week low of $10.41 and a fifty-two week high of $129.84. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.79 and a current ratio of 2.95. The company has a market capitalization of $2.34 billion, a P/E ratio of -7.41 and a beta of 0.54. The company has a fifty day moving average of $20.74 and a 200 day moving average of $20.02.</p>
<div class="lb-trans"><p>Sarepta Therapeutics 股票在周五开盘价为 22.29 美元。Sarepta Therapeutics, Inc. 的 52 周低点为 10.41 美元，52 周高点为 129.84 美元。该公司的债务与股本比率为 0.78，速动比率为 1.79，流动比率为 2.95。该公司的市值为 23.4 亿美元，市盈率为 -7.41，贝塔值为 0.54。该公司的 50 日移动平均线为 20.74 美元，200 日移动平均线为 20.02 美元。</p>
</div><p>Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last announced its quarterly earnings data on Monday, November 3rd. The biotechnology company reported ($0.13) EPS for the quarter, missing the consensus estimate of $0.02 by ($0.15). The business had revenue of $399.36 million during the quarter, compared to analysts' expectations of $331.51 million. Sarepta Therapeutics had a negative net margin of 11.25% and a negative return on equity of 4.85%. Sarepta Therapeutics's revenue was down 14.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.62 earnings per share. On average, sell-side analysts anticipate that Sarepta Therapeutics, Inc. will post 2.67 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Sarepta Therapeutics（NASDAQ:SRPT - 获取免费报告）最近在 11 月 3 日星期一公布了季度财报。该生物技术公司报告季度每股收益为（0.13）美元，低于市场共识预期的 0.02 美元，差距为（0.15）美元。该公司在季度内的收入为 3.9936 亿美元，而分析师预期为 3.3151 亿美元。Sarepta Therapeutics 的净利润率为 -11.25%，股本回报率为 -4.85%。Sarepta Therapeutics 的收入同比下降了 14.5%。在去年同期，该公司每股收益为 0.62 美元。平均而言，卖方分析师预计 Sarepta Therapeutics, Inc. 在当前财政年度的每股收益将达到 2.67 美元。</p>
</div><h2>Sarepta Therapeutics Profile</h2>
<div class="lb-trans"><h2>Sarepta Therapeutics 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta's core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company's mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.</p>
<div class="lb-trans"><p>Sarepta Therapeutics, Inc. 是一家生物制药公司，专注于针对罕见神经肌肉疾病的精准基因治疗的发现和开发。公司总部位于马萨诸塞州剑桥，Sarepta 的核心专长在于设计针对 RNA 的疗法和基因疗法，以解决潜在的基因突变。公司的使命是通过创新的治疗方式改变杜氏肌营养不良症（DMD）及相关疾病患者的治疗模式。</p>
</div><p>Sarepta's commercial products include several exon-skipping therapies approved by the U.S.</p>
<div class="lb-trans"><p>Sarepta 的商业产品包括几种已获得美国批准的外显子跳跃疗法。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Sarepta Therapeutics</li>
<li>Put $1,000 into this stock by Jan 1 [Not NVDA]</li>
<li>Turn your &#34;dead money&#34; into $306+ monthly (starting this month)</li>
<li>Washington prepares for war</li>
<li>Strange Crystal Metal Outperforms Silicon Up to 100X</li>
<li>33,000% boom from weird new “AI Fuel?”</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Sarepta Therapeutics</li>
<li>在 1 月 1 日之前投资 1,000 美元于此股票 [非 NVDA]</li>
<li>将你的 “死钱” 转变为每月 306 美元以上（从本月开始）</li>
<li>华盛顿为战争做准备</li>
<li>奇怪的水晶金属性能超越硅达 100 倍</li>
<li>33,000% 的奇怪新 “AI 燃料” 带来的繁荣？</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding SRPT?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report).</p>
<div class="lb-trans"><p><strong>想知道其他对 SRPT 持有的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取 Sarepta Therapeutics, Inc. (NASDAQ:SRPT - 免费报告) 的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1JQVA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=SRPT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Sarepta Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Sarepta Therapeutics 吗？</h2>
</div><p>Before you consider Sarepta Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Sarepta Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sarepta Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Sarepta Therapeutics 并不在名单上。</p>
</div><p>While Sarepta Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Sarepta Therapeutics 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Assenagon Asset Management S.A. 出售了 838,457 股 Sarepta 医疗公司的股票，代码为 $SRPT